The U.S. Food and Drug Administration has approved a groundbreaking clinical trial exploring the use of botanical psilocybin to treat veterans and first responders suffering from both post-traumatic stress disorder (PTSD) and alcohol use disorder (AUD). The study, led by Dr. Nathan Sackett at the University of Washington, will assess the safety of Filament Health’s psilocybin drug, PEX010, administered in a single 25 mg dose alongside psychological support.
This marks the first time psilocybin-assisted therapy will be evaluated for individuals with both PTSD and AUD—two conditions that often overlap but lack effective dual treatments, particularly among military and emergency personnel. The trial, funded by the State of Washington, is currently enrolling participants, with results expected by fall 2026.
Filament Health CEO Benjamin Lightburn emphasized the urgent need for innovative mental health solutions for those who have served their communities.
Read the full story at The Marijuana Herald.